Quince Therapeutics, Inc. (QNCX)
31.32
+0.77
(+2.52%)
USD |
NASDAQ |
Sep 04, 16:00
31.18
-0.14
(-0.43%)
After-Hours: 20:00
Quince Therapeutics Total Liabilities (Quarterly) : 15.51M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.51M |
| March 31, 2026 | 10.95M |
| December 31, 2025 | 129.35M |
| September 30, 2025 | 108.84M |
| June 30, 2025 | 105.47M |
| March 31, 2025 | 88.51M |
| December 31, 2024 | 96.01M |
| September 30, 2024 | 81.59M |
| June 30, 2024 | 87.86M |
| March 31, 2024 | 85.12M |
| December 31, 2023 | 95.12M |
| September 30, 2023 | 2.253M |
| June 30, 2023 | 1.952M |
| March 31, 2023 | 3.115M |
| December 31, 2022 | 4.352M |
| Date | Value |
|---|---|
| September 30, 2022 | 5.246M |
| June 30, 2022 | 6.331M |
| March 31, 2022 | 9.75M |
| December 31, 2021 | 14.64M |
| September 30, 2021 | 14.76M |
| June 30, 2021 | 19.31M |
| March 31, 2021 | 18.04M |
| December 31, 2020 | 17.20M |
| September 30, 2020 | 16.65M |
| June 30, 2020 | 13.74M |
| March 31, 2020 | 13.16M |
| December 31, 2019 | 8.892M |
| September 30, 2019 | 6.127M |
| June 30, 2019 | 7.025M |
| March 31, 2019 | 4.485M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.641M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 124.00M |
| Shareholders Equity (Quarterly) | 108.49M |
| Current Ratio | 14.52 |
| Net Debt Paydown Yield | 17.03% |